Jiangsu CoWin Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	209.77	161.28	255.47	348.34	1,032	127.83
Short-Term Investments	-	306.8	60.54	90.01	-	-
Trading Asset Securities	546.26	420.14	417.04	545.28	402.59	233.42
Cash & Short-Term Investments	756.03	888.22	733.05	983.64	1,434	361.25
Cash Growth	-21.27%	21.17%	-25.48%	-31.41%	297.00%	5.63%
Accounts Receivable	70.82	59.54	43.28	58.96	129.64	36.56
Other Receivables	3	2.2	2.45	-	0.31	-
Receivables	73.81	61.73	45.72	58.96	129.95	36.56
Inventory	43.34	48.77	45.87	32.04	52.53	32.62
Other Current Assets	28.57	34.71	8.76	10.04	10.05	7.72
Total Current Assets	901.75	1,033	833.4	1,085	1,627	438.16
Property, Plant & Equipment	377.01	342.02	381.13	394.39	246.43	159.44
Long-Term Investments	110.01	29.35	296.81	256.71	-	-
Goodwill	1.08	1.08	1.08	-	4.27	-
Other Intangible Assets	47.33	48.81	49.97	29.77	29.35	30.15
Long-Term Deferred Tax Assets	33.01	27.18	32.5	29.83	17.11	4
Long-Term Deferred Charges	11.08	12.6	20.73	24.8	11.36	13.82
Other Long-Term Assets	4.82	2.3	2.52	2.04	20.06	3.2
Total Assets	1,486	1,497	1,618	1,822	1,955	648.77

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	20.64	9.95	13.48	47.53	44.07	10.55
Accrued Expenses	9.38	23.03	23.1	16.69	21.69	22.12
Short-Term Debt	-	4	6.01	-	-	-
Current Portion of Leases	-	5.91	12.12	13.65	9.05	5.67
Current Income Taxes Payable	0.92	-	-	-	9.56	8.21
Current Unearned Revenue	19.86	25.01	9.63	4.48	5.75	10.28
Other Current Liabilities	5.68	6.16	19.65	2.51	3.03	3.58
Total Current Liabilities	60.97	74.07	84	84.86	93.15	60.41
Long-Term Leases	38.85	4.54	9.71	19.31	31.72	34.33
Long-Term Unearned Revenue	50.96	52.53	30.25	30.11	29.58	5.67
Long-Term Deferred Tax Liabilities	9.91	7.21	7.75	8.32	9.1	0.06
Other Long-Term Liabilities	0.2	0.12	0.09	0.06	0.05	0.04
Total Liabilities	160.89	138.47	131.79	142.67	163.6	100.51

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	112.49	112.49	112.49	112.23	93.52	69.87
Additional Paid-In Capital	1,393	1,391	1,394	1,391	1,393	344.45
Retained Earnings	-139.72	-104.54	2.87	160.08	293.13	133.87
Treasury Stock	-47.67	-47.67	-43.66	-	-	-
Comprehensive Income & Other	0.33	0.3	0.33	0.3	0.27	0.07
Total Common Equity	1,318	1,351	1,466	1,664	1,780	548.26
Minority Interest	6.75	7.18	20.56	15.88	11.31	-
Shareholders' Equity	1,325	1,358	1,486	1,680	1,792	548.26
Total Liabilities & Equity	1,486	1,497	1,618	1,822	1,955	648.77

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	43.35	14.45	27.84	32.95	40.77	39.99
Net Cash (Debt)	712.69	873.77	705.21	950.68	1,393	321.25
Net Cash Growth	-23.72%	23.90%	-25.82%	-31.77%	333.73%	-6.07%
Net Cash Per Share	6.51	7.97	6.32	8.45	15.00	3.81
Filing Date Shares Outstanding	110.25	109.93	110.11	112.49	112.23	83.85
Total Common Shares Outstanding	110.25	109.93	110.11	112.23	112.23	83.85
Working Capital	840.78	959.36	749.41	999.82	1,534	377.75
Book Value Per Share	11.96	12.29	13.31	14.82	15.86	6.54
Tangible Book Value	1,270	1,301	1,415	1,634	1,747	518.11
Tangible Book Value Per Share	11.52	11.84	12.85	14.56	15.56	6.18
Buildings	-	216.23	235.28	234.89	0.66	0.66
Machinery	-	216.99	207.97	188.41	133.11	75.91
Construction In Progress	-	0.63	0.37	-	110.9	64.81